These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 20975003)

  • 1. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.
    Onuma Y; Serruys PW; Perkins LE; Okamura T; Gonzalo N; García-García HM; Regar E; Kamberi M; Powers JC; Rapoza R; van Beusekom H; van der Giessen W; Virmani R
    Circulation; 2010 Nov; 122(22):2288-300. PubMed ID: 20975003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.
    Farooq V; Serruys PW; Heo JH; Gogas BD; Onuma Y; Perkins LE; Diletti R; Radu MD; Räber L; Bourantas CV; Zhang Y; van Remortel E; Pawar R; Rapoza RJ; Powers JC; van Beusekom HM; Garcìa-Garcìa HM; Virmani R
    JACC Cardiovasc Interv; 2013 May; 6(5):523-32. PubMed ID: 23702016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies.
    Gogas BD; Radu M; Onuma Y; Perkins L; Powers JC; Gomez-Lara J; Farooq V; Garcia-Garcia HM; Diletti R; Rapoza R; Virmani R; Serruys PW
    Int J Cardiovasc Imaging; 2012 Mar; 28(3):499-511. PubMed ID: 21503708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterisation of bioresorbable vascular scaffold strut interfaces using optical coherence tomography with Gaussian line spread function analysis.
    Sheehy A; Gutiérrez-Chico JL; Diletti R; Oberhauser JP; Glauser T; Harrington J; Kossuth MB; Rapoza RJ; Onuma Y; Serruys PW
    EuroIntervention; 2012 Feb; 7(10):1227-35. PubMed ID: 22222916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold.
    Karanasos A; Simsek C; Gnanadesigan M; van Ditzhuijzen NS; Freire R; Dijkstra J; Tu S; Van Mieghem N; van Soest G; de Jaegere P; Serruys PW; Zijlstra F; van Geuns RJ; Regar E
    J Am Coll Cardiol; 2014 Dec; 64(22):2343-56. PubMed ID: 25465421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model.
    Otsuka F; Pacheco E; Perkins LE; Lane JP; Wang Q; Kamberi M; Frie M; Wang J; Sakakura K; Yahagi K; Ladich E; Rapoza RJ; Kolodgie FD; Virmani R
    Circ Cardiovasc Interv; 2014 Jun; 7(3):330-42. PubMed ID: 24895447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
    Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
    Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
    Diletti R; Karanasos A; Muramatsu T; Nakatani S; Van Mieghem NM; Onuma Y; Nauta ST; Ishibashi Y; Lenzen MJ; Ligthart J; Schultz C; Regar E; de Jaegere PP; Serruys PW; Zijlstra F; van Geuns RJ
    Eur Heart J; 2014 Mar; 35(12):777-86. PubMed ID: 24394380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.
    Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R
    EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
    Gomez-Lara J; Diletti R; Brugaletta S; Onuma Y; Farooq V; Thuesen L; McClean D; Koolen J; Ormiston JA; Windecker S; Whitbourn R; Dudek D; Dorange C; Veldhof S; Rapoza R; Regar E; Garcia-Garcia HM; Serruys PW
    EuroIntervention; 2012 Jun; 8(2):214-24. PubMed ID: 22030265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold.
    van Geuns RJ; Gogas BD; Farooq V; Regar E; Serruys PW
    Int J Cardiol; 2011 Dec; 153(2):e43-5. PubMed ID: 21392836
    [No Abstract]   [Full Text] [Related]  

  • 16. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application.
    Farooq V; Onuma Y; Radu M; Okamura T; Gomez-Lara J; Brugaletta S; Gogas BD; van Geuns RJ; Regar E; Schultz C; Windecker S; Lefèvre T; Brueren BR; Powers J; Perkins LL; Rapoza RJ; Virmani R; García-García HM; Serruys PW
    EuroIntervention; 2011 Jul; 7(3):386-99. PubMed ID: 21729842
    [No Abstract]   [Full Text] [Related]  

  • 17. First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: insights from optical coherence tomography.
    Grasso C; Attizzani GF; Patané M; Ohno Y; Capodanno D; Tamburino C
    Int J Cardiol; 2013 Oct; 168(4):4490-1. PubMed ID: 23890924
    [No Abstract]   [Full Text] [Related]  

  • 18. Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial.
    Brugaletta S; Gomez-Lara J; Bruining N; Radu MD; van Geuns RJ; Thuesen L; McClean D; Koolen J; Windecker S; Whitbourn R; Oberhauser J; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    EuroIntervention; 2012 Jul; 8(3):352-8. PubMed ID: 22130182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year longitudinal evaluation of a second-generation thin-strut sirolimus-eluting bioresorbable coronary scaffold with hybrid cell design in porcine coronary arteries.
    Gasior P; Cheng Y; Xia J; Conditt GB; McGregor JC; Virmani R; Granada JF; Kaluza GL
    Cardiol J; 2020; 27(2):115-125. PubMed ID: 30155861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
    Diletti R; Onuma Y; Farooq V; Gomez-Lara J; Brugaletta S; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Smits P; Koolen J; Meredith I; Li D; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    J Am Coll Cardiol; 2011 Jul; 58(3):258-64. PubMed ID: 21737016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.